JP7099956B2 - がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 - Google Patents

がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 Download PDF

Info

Publication number
JP7099956B2
JP7099956B2 JP2018528691A JP2018528691A JP7099956B2 JP 7099956 B2 JP7099956 B2 JP 7099956B2 JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018528691 A JP2018528691 A JP 2018528691A JP 7099956 B2 JP7099956 B2 JP 7099956B2
Authority
JP
Japan
Prior art keywords
ferritin
mica
protein
vaccine
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018528691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536002A (ja
JP2018536002A5 (enExample
Inventor
カイ ウチェープフェニグ
サムヤ バドリナス
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2018536002A publication Critical patent/JP2018536002A/ja
Publication of JP2018536002A5 publication Critical patent/JP2018536002A5/ja
Priority to JP2022105405A priority Critical patent/JP7564842B2/ja
Application granted granted Critical
Publication of JP7099956B2 publication Critical patent/JP7099956B2/ja
Priority to JP2024167997A priority patent/JP2024177207A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018528691A 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 Active JP7099956B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022105405A JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US62/263,377 2015-12-04
US201662422454P 2016-11-15 2016-11-15
US62/422,454 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105405A Division JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Publications (3)

Publication Number Publication Date
JP2018536002A JP2018536002A (ja) 2018-12-06
JP2018536002A5 JP2018536002A5 (enExample) 2020-01-16
JP7099956B2 true JP7099956B2 (ja) 2022-07-12

Family

ID=57590885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018528691A Active JP7099956B2 (ja) 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Country Status (24)

Country Link
US (3) US10993971B2 (enExample)
EP (1) EP3383426A1 (enExample)
JP (3) JP7099956B2 (enExample)
KR (1) KR20180088458A (enExample)
CN (1) CN108770343A (enExample)
AU (3) AU2016362597C1 (enExample)
BR (1) BR112018010705A8 (enExample)
CA (1) CA3005910A1 (enExample)
CL (3) CL2018001470A1 (enExample)
CO (1) CO2018006642A2 (enExample)
CR (2) CR20180350A (enExample)
CU (2) CU20210061A7 (enExample)
EA (1) EA201891287A1 (enExample)
IL (1) IL259490A (enExample)
MX (2) MX2018006785A (enExample)
MY (1) MY199248A (enExample)
NZ (1) NZ742663A (enExample)
PE (2) PE20181158A1 (enExample)
PH (1) PH12018501170A1 (enExample)
RU (2) RU2021109510A (enExample)
SG (1) SG11201804597TA (enExample)
TN (1) TN2018000187A1 (enExample)
WO (1) WO2017096374A1 (enExample)
ZA (1) ZA202204223B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112584858A (zh) 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006001A1 (en) 2002-05-10 2004-01-08 Carter Daniel C. Ferritin fusion proteins for use in vaccines and other applications
JP2015508757A (ja) 2012-02-07 2015-03-23 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20100111973A1 (en) 2006-09-22 2010-05-06 Glenn Dranoff Methods for treating mica-related disorders
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US20120269721A1 (en) 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
EP2514718A4 (en) 2009-12-18 2013-09-04 Kao Corp METHOD FOR PRODUCING MESOPOROUS SILICONE ARTICLES
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
JP2014534807A (ja) * 2011-09-23 2014-12-25 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
ES2773895T3 (es) 2012-04-16 2020-07-15 Harvard College Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
WO2014140904A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
EP3116903A2 (en) * 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006001A1 (en) 2002-05-10 2004-01-08 Carter Daniel C. Ferritin fusion proteins for use in vaccines and other applications
JP2015508757A (ja) 2012-02-07 2015-03-23 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤

Also Published As

Publication number Publication date
IL259490A (en) 2018-07-31
PE20230495A1 (es) 2023-03-23
PH12018501170A1 (en) 2019-01-21
RU2747296C2 (ru) 2021-05-04
BR112018010705A8 (pt) 2019-02-26
CL2021001256A1 (es) 2021-12-31
JP2018536002A (ja) 2018-12-06
AU2025213685A1 (en) 2025-08-28
MY199248A (en) 2023-10-23
JP2022130623A (ja) 2022-09-06
SG11201804597TA (en) 2018-06-28
CU20180050A7 (es) 2018-11-06
RU2018123307A3 (enExample) 2020-04-20
BR112018010705A2 (pt) 2018-11-21
JP2024177207A (ja) 2024-12-19
CR20180350A (es) 2018-10-02
RU2018123307A (ru) 2020-01-13
AU2016362597A1 (en) 2018-06-07
KR20180088458A (ko) 2018-08-03
CL2018001470A1 (es) 2018-12-21
US10993971B2 (en) 2021-05-04
WO2017096374A1 (en) 2017-06-08
MX2022010194A (es) 2022-09-19
US20250064863A1 (en) 2025-02-27
AU2022201940A1 (en) 2022-04-14
CR20230116A (es) 2023-05-05
TN2018000187A1 (en) 2019-10-04
US20210299186A1 (en) 2021-09-30
ZA202204223B (en) 2023-12-20
CL2023003217A1 (es) 2024-06-28
MX2018006785A (es) 2018-11-09
CU20210061A7 (es) 2022-02-04
PE20181158A1 (es) 2018-07-19
JP7564842B2 (ja) 2024-10-09
CU24609B1 (es) 2022-06-06
EP3383426A1 (en) 2018-10-10
US20180353581A1 (en) 2018-12-13
CO2018006642A2 (es) 2018-07-10
AU2016362597B2 (en) 2022-02-17
CN108770343A (zh) 2018-11-06
AU2022201940B2 (en) 2025-05-08
AU2016362597C1 (en) 2022-05-26
RU2021109510A (ru) 2021-04-16
CA3005910A1 (en) 2017-06-08
NZ742663A (en) 2023-02-24
EA201891287A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
JP7564842B2 (ja) がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2019505512A (ja) 治療用抗癌ネオエピトープワクチン
TW200400970A (en) Immunogenic compositions
US7217791B2 (en) Compositions and methods for treating or preventing pneumococcal infection
RU2385163C2 (ru) Профилактическая противораковая вакцина
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
JP2023507347A (ja) ネオエピトープをコードするコンストラクトを使用する核酸ワクチン接種
CN121620389A (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗
CA2588573C (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor their use in the treatment of cancer
EP1056851A1 (en) TUMOR ASSOCIATED ANTIGEN 791Tgp72
EA041345B1 (ru) Вакцинация с использованием альфа3-домена mica/b для лечения рака
TWI398262B (zh) 腫瘤相關抗原之免疫性肽類及其於癌症治療上的用途
BR122026004117A2 (pt) Composição de vacina compreendendo um peptídeo no domínio mic alfa 3, proteína de fusão, nanopartícula e uso de um peptídeo no domínio mic alfa 3
HK1113374B (en) Immunotherapeutic formulations with interleukin-2-neutralising capacity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220630

R150 Certificate of patent or registration of utility model

Ref document number: 7099956

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250